Physician profile
Joseph Sullivan
NPI 1982691689
$21,370.13
in general payments reported to CMS, 2019-2025
73 companies · $3,003 in 2025
The $3,003 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,118 · 2020: $2,685 · 2021: $3,083 · 2022: $2,527 · 2023: $2,762 · 2024: $3,193 · 2025: $3,003.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,451 · Education: $506.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,451.16 |
| Education | $505.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,639.50 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,646.99 | 2019-2025 | Enhertu, Imfinzi, Calquence |
| Pfizer INC. | $1,077.93 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,003.71 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Coherus Oncology, INC. | $900.00 | 2021 | |
| Seagen INC. | $851.79 | 2019-2023 | Adcetris, Tivdak, Tukysa |
| Novartis Pharmaceuticals Corporation | $816.73 | 2019-2025 | Piqray, Kisqali |
| Celgene Corporation | $728.47 | 2020-2025 | Reblozyl, Pomalyst, Opdualag |
| Ipsen Biopharmaceuticals, INC | $623.64 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $613.30 | 2019-2025 | Opdivo, Opdualag |
| Janssen Biotech, INC. | $561.52 | 2019-2024 | Imbruvica, Darzalex, Rybrevant |
| Amgen INC. | $546.14 | 2019-2025 | Kyprolis, Krystexxa, Blincyto |
| Incyte Corporation | $507.92 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Lilly USA, LLC | $478.29 | 2019-2024 | Verzenio, Jaypirca, Retevmo |
| Daiichi Sankyo INC. | $469.89 | 2019-2025 | Enhertu, Datroway, Vanflyta |
Show all 73 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $467.76 | 2019-2025 | Tecentriq, Alecensa, Tecentriq Hybreza |
| Takeda Pharmaceuticals U.S.A., INC. | $464.48 | 2019-2025 | Fruzaqla, Iclusig, Alunbrig |
| Glaxosmithkline, LLC. | $413.02 | 2019-2025 | Ojjaara, Jemperli, Zejula |
| Astellas Pharma US INC | $369.40 | 2019-2025 | Padcev, Xospata, Vyloy |
| Gilead Sciences, INC. | $307.54 | 2019-2025 | Trodelvy |
| Exelixis INC. | $300.19 | 2019-2025 | Cabometyx |
| Kite Pharma, INC. | $291.47 | 2021-2024 | Yescarta |
| Eisai INC. | $288.91 | 2022-2025 | |
| Abbvie INC. | $285.07 | 2020-2025 | |
| Secura Bio, INC. | $260.55 | 2019-2022 | |
| Sobi, INC | $254.16 | 2023-2025 | |
| Servier Pharmaceuticals LLC | $229.69 | 2021-2025 | |
| G1 Therapeutics, INC. | $229.23 | 2022-2023 | Cosela |
| Taiho Oncology, INC. | $216.65 | 2019-2025 | |
| Array Biopharma INC | $202.13 | 2020-2025 | Braftovi, Mektovi, Lorbrena |
| Pharmacosmos Therapeutics INC. | $187.72 | 2024-2025 | Monoferric, Cosela |
| Rigel Pharmaceuticals, INC. | $181.29 | 2019-2024 | Tavalisse, Rezlidhia |
| Pharmacyclics LLC, An Abbvie Company | $170.02 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $167.24 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $166.88 | 2019-2025 | Zepzelca |
| Mirati Therapeutics, INC. | $163.79 | 2023-2024 | Krazati |
| Regeneron Healthcare Solutions, INC. | $144.53 | 2023-2025 | Libtayo |
| Foundation Medicine, INC. | $138.14 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $136.42 | 2019-2024 | |
| Karyopharm Therapeutics INC. | $129.63 | 2020-2024 | Xpovio |
| Octapharma USA, INC. | $123.53 | 2020-2024 | Octagam Immune Globulin (Human) |
| Bayer Healthcare Pharmaceuticals INC. | $109.37 | 2019-2025 | |
| Puma Biotechnology, INC. | $106.08 | 2020-2025 | |
| Aveo Pharmaceuticals, INC. | $97.49 | 2022-2025 | |
| Morphosys, US INC. | $96.10 | 2021-2023 | Monjuvi |
| Tesaro, INC. | $89.01 | 2019 | |
| Dova Pharmaceuticals | $84.86 | 2020-2021 | |
| Amag Pharmaceuticals, INC. | $74.74 | 2019-2020 | |
| Emd Serono, INC. | $74.40 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $73.56 | 2019-2025 | Ultomiris |
| Global Blood Therapeutics, INC. | $63.43 | 2020-2022 | |
| Legend Biotech USA INC. | $58.68 | 2025 | Carvykti |
| Csl Behring | $58.38 | 2023 | Idelvion, Afstyla |
| Sun Pharmaceutical Industries INC. | $57.17 | 2021-2022 | |
| Tg Therapeutics, INC. | $51.74 | 2021-2022 | |
| Epizyme, INC. | $49.71 | 2020-2021 | |
| Beone Medicines USA, INC. | $39.75 | 2025 | Brukinsa |
| Agios Pharmaceuticals, INC. | $39.68 | 2019-2020 | |
| Adc Therapeutics America, INC. | $37.61 | 2024-2025 | |
| Tersera Therapeutics LLC | $37.52 | 2023-2024 | Xermelo, Zoladex |
| Cti Biopharma Corp. | $36.90 | 2023 | Vonjo |
| Horizon Therapeutics Plc | $36.75 | 2019-2020 | |
| Dendreon Pharmaceuticals LLC | $31.13 | 2025 | Provenge |
| Clovis Oncology, INC. | $30.70 | 2019-2020 | |
| Geron Corporation | $26.84 | 2025 | Rytelo |
| Teva Pharmaceuticals USA, INC. | $26.48 | 2019-2020 | |
| Iovance Biotherapeutics, INC. | $25.29 | 2025 | Amtagvi |
| Adaptive Biotechnologies Corporation | $18.45 | 2025 | Clonoseq |
| Pharmaessentia USA Corporation | $17.58 | 2022 | |
| Tela Bio, INC. | $17.33 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Novocure INC. | $16.25 | 2025 | Optune Lua (Novottf-200t) |
| Fresenius Kabi USA, LLC | $16.18 | 2021 | |
| Sumitomo Pharma America, INC. | $15.71 | 2024 | Orgovyx |
Drugs and devices associated with these payments
Enhertu $813Keytruda $438Imfinzi $394Reblozyl $387Imbruvica $311Calquence $260Cosela $252Sarclisa $242Opdivo $237Adcetris $208Lynparza $197Lenvima $197Tukysa $189Vonjo $188Cabometyx $184Ibrance $168Tibsovo $167Krazati $164Tivdak $162Xtandi $159Ojjaara $158Jakafi $155Kisqali $151Yescarta $145Libtayo $145Orgovyx $139Verzenio $133Monoferric $130Monjuvi $126Elrexfio $120Darzalex $120Trodelvy $119Zepzelca $117Padcev $117Welireg $108Jaypirca $101Pluvicto $90.54Inqovi $89.30Lonsurf $89.30Braftovi $88.53Mektovi $88.53Talzenna $84.07Tecentriq $83.81Jemperli $83.11Fotivda $82.78Scemblix $82.55Synagis $67.83Bosulif $64.02Zynyz $63.93Opdualag $62.30Zejula $61.83Pomalyst $61.66Comirnaty $60.76Carvykti $58.68Afstyla $58.38Idelvion $58.38Lorbrena $58.09Retevmo $56.81Xpovio $56.02Piqray $52.82Epkinly $50.85Rybrevant $48.66Fruzaqla $46.61Lutathera $46.38Alecensa $45.97Xospata $41.81Nerlynx $40.73Brukinsa $39.75Tecvayli $38.69Talvey $38.69Iclusig $37.39Vyloy $36.91Doptelet $35.44Kyprolis $35.21Jevtana $34.65Ultomiris $33.69Alunbrig $33.30Octagam Immune Globulin (Human) $32.20Oxbryta $32.13Provenge $31.13Ninlaro $30.51Paxlovid $30.50Erleada $28.28Inlyta $27.99Rytelo $26.84Venclexta $25.76Fabhalta $25.62Amtagvi $25.29Rezlidhia $24.88Tavalisse $24.88Blenrep $24.38Datroway $24.34Pemazyre $22.69Elitek $22.26Xermelo $22.15Nubeqa $21.52Xofigo $21.52Elahere $21.02Krystexxa $21.00Tecentriq Hybreza $20.77
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.